250 filings
Page 4 of 13
8-K
0he0b
25 Feb 21
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:04pm
8-K
8c46ia
3 Feb 21
Regulation FD Disclosure
4:16pm
8-K
ddc00 gshoii7
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am
8-K
1f8 h8wysz
28 Jan 21
Departure of Directors or Certain Officers
9:54pm
8-K
h3n8el
19 Nov 20
Entry into a Material Definitive Agreement
4:35pm
8-K
owhuo3dcwyr49o35h7fc
19 Nov 20
Regulation FD Disclosure
11:34am
8-K
v5l c3965zongamu73go
12 Nov 20
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
4:03pm
8-K
4lnn 3gub3902v8
14 Oct 20
Entry into a Material Definitive Agreement
6:04am
8-K
8kslvq
8 Oct 20
Entry into a Material Definitive Agreement
3:40pm
8-K
e5ekvmn68jizlf
23 Sep 20
Regulation FD Disclosure
1:15pm
8-K
zx88651yci 6lg
15 Sep 20
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
12:00am
8-K
qh44g
27 Aug 20
Vaxart Appoints Karen J. Wilson to its Board of Directors
8:09am
8-K
ftcpybgascc vqak
6 Aug 20
Vaxart Announces Second Quarter 2020 Results
4:07pm
8-K
st7vpx7kgh 8q5
13 Jul 20
Other Events
4:13pm
8-K
t32pa bpy
8 Jul 20
Results of Operations and Financial Condition
8:51am
8-K
uyzuhcfe8a oddb
30 Jun 20
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
5:24pm
8-K
8j9r0r2
23 Jun 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:24pm
8-K
9u1mw2kftjl8wbobydnt
18 Jun 20
Regulation FD Disclosure
1:26pm
8-K
c5t5lei sgxd
15 Jun 20
Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
5:25pm
8-K
fyf0qfr5
9 Jun 20
Departure of Directors or Certain Officers
4:26pm